Elizabeth L. Hohmann, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium Infections | 14 | 2023 | 559 | 2.510 |
Why?
|
| Feces | 12 | 2020 | 1515 | 1.840 |
Why?
|
| Listeria monocytogenes | 6 | 2013 | 246 | 1.320 |
Why?
|
| Salmonella typhi | 10 | 2018 | 200 | 1.070 |
Why?
|
| Enterocolitis, Pseudomembranous | 4 | 2017 | 264 | 1.050 |
Why?
|
| Salmonella typhimurium | 10 | 2010 | 348 | 0.950 |
Why?
|
| Transplantation | 3 | 2015 | 221 | 0.950 |
Why?
|
| Bacteremia | 8 | 2020 | 985 | 0.940 |
Why?
|
| Secondary Prevention | 4 | 2018 | 1479 | 0.890 |
Why?
|
| Biological Therapy | 2 | 2016 | 140 | 0.880 |
Why?
|
| Vaccines, Attenuated | 8 | 2013 | 315 | 0.740 |
Why?
|
| Bacterial Vaccines | 6 | 2013 | 400 | 0.690 |
Why?
|
| Salmonella Infections | 4 | 2010 | 172 | 0.680 |
Why?
|
| Alkaline Phosphatase | 9 | 2014 | 865 | 0.640 |
Why?
|
| Salmonella Vaccines | 3 | 2007 | 8 | 0.630 |
Why?
|
| Quarantine | 1 | 2020 | 187 | 0.610 |
Why?
|
| Intestines | 5 | 2020 | 1912 | 0.610 |
Why?
|
| Listeriosis | 5 | 2013 | 147 | 0.590 |
Why?
|
| Cytomegalovirus Infections | 2 | 2014 | 839 | 0.590 |
Why?
|
| Diarrhea | 5 | 2016 | 1320 | 0.570 |
Why?
|
| Colon | 2 | 2014 | 1804 | 0.530 |
Why?
|
| Bacterial Proteins | 14 | 2013 | 3861 | 0.500 |
Why?
|
| Typhoid Fever | 6 | 2018 | 195 | 0.500 |
Why?
|
| Immunocompromised Host | 4 | 2017 | 867 | 0.470 |
Why?
|
| Gastrointestinal Tract | 3 | 2018 | 840 | 0.460 |
Why?
|
| Capsules | 4 | 2022 | 193 | 0.440 |
Why?
|
| Colitis, Ulcerative | 2 | 2014 | 1930 | 0.400 |
Why?
|
| Influenza, Human | 3 | 2012 | 1540 | 0.400 |
Why?
|
| Genetic Vectors | 6 | 2011 | 3417 | 0.390 |
Why?
|
| Ethics Committees, Research | 3 | 2019 | 196 | 0.380 |
Why?
|
| Orthomyxoviridae | 1 | 2012 | 148 | 0.380 |
Why?
|
| Viral Core Proteins | 1 | 2011 | 158 | 0.360 |
Why?
|
| Cholera Toxin | 1 | 2013 | 562 | 0.360 |
Why?
|
| Influenza Vaccines | 2 | 2011 | 781 | 0.350 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2011 | 450 | 0.350 |
Why?
|
| Urease | 2 | 2000 | 43 | 0.350 |
Why?
|
| Bacteriological Techniques | 2 | 2013 | 277 | 0.340 |
Why?
|
| Hepatic Encephalopathy | 2 | 2022 | 144 | 0.340 |
Why?
|
| Adenosine Monophosphate | 2 | 2021 | 233 | 0.330 |
Why?
|
| Escherichia coli | 5 | 2019 | 4220 | 0.330 |
Why?
|
| Respiratory System | 1 | 2012 | 565 | 0.320 |
Why?
|
| Immunity, Mucosal | 2 | 2011 | 494 | 0.320 |
Why?
|
| Energy Metabolism | 1 | 2020 | 2901 | 0.310 |
Why?
|
| Interferon-gamma | 4 | 2013 | 3169 | 0.310 |
Why?
|
| Alanine | 2 | 2021 | 613 | 0.300 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 998 | 0.290 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 1950 | 0.290 |
Why?
|
| Actinomycosis | 1 | 2006 | 19 | 0.280 |
Why?
|
| Antigens, Bacterial | 5 | 2013 | 1150 | 0.280 |
Why?
|
| Opportunistic Infections | 1 | 2009 | 376 | 0.270 |
Why?
|
| Helicobacter pylori | 2 | 2000 | 382 | 0.260 |
Why?
|
| Insulin Resistance | 1 | 2020 | 3974 | 0.260 |
Why?
|
| Administration, Oral | 8 | 2016 | 4041 | 0.260 |
Why?
|
| Gene Products, gag | 1 | 2006 | 318 | 0.250 |
Why?
|
| Fractures, Open | 1 | 2006 | 107 | 0.250 |
Why?
|
| Abdominal Abscess | 1 | 2006 | 153 | 0.250 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2006 | 236 | 0.240 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 2 | 1996 | 40 | 0.230 |
Why?
|
| Pilot Projects | 6 | 2024 | 8730 | 0.220 |
Why?
|
| Antibodies, Bacterial | 5 | 2013 | 1481 | 0.220 |
Why?
|
| Tibial Fractures | 1 | 2006 | 276 | 0.210 |
Why?
|
| Bedding and Linens | 1 | 2023 | 41 | 0.210 |
Why?
|
| Adult | 36 | 2024 | 223542 | 0.210 |
Why?
|
| Humans | 70 | 2024 | 768451 | 0.200 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 1885 | 0.200 |
Why?
|
| Salmonella paratyphi A | 2 | 2013 | 47 | 0.200 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2013 | 126 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2019 | 1064 | 0.200 |
Why?
|
| Consumer Product Safety | 1 | 2002 | 122 | 0.190 |
Why?
|
| Type C Phospholipases | 1 | 2002 | 287 | 0.190 |
Why?
|
| Treatment Outcome | 17 | 2024 | 65409 | 0.190 |
Why?
|
| Male | 38 | 2024 | 364781 | 0.190 |
Why?
|
| Rectum | 1 | 2006 | 902 | 0.190 |
Why?
|
| Recurrence | 7 | 2023 | 8510 | 0.190 |
Why?
|
| Middle Aged | 30 | 2024 | 223418 | 0.180 |
Why?
|
| Genes, Bacterial | 4 | 2002 | 1076 | 0.180 |
Why?
|
| Wounds, Gunshot | 1 | 2006 | 589 | 0.180 |
Why?
|
| Adolescent | 19 | 2022 | 89168 | 0.170 |
Why?
|
| Influenza A virus | 1 | 2004 | 460 | 0.170 |
Why?
|
| Bradycardia | 1 | 2022 | 305 | 0.170 |
Why?
|
| Graft vs Host Disease | 3 | 2024 | 3042 | 0.170 |
Why?
|
| Fever | 2 | 2022 | 1622 | 0.170 |
Why?
|
| AIDS Vaccines | 1 | 2006 | 900 | 0.170 |
Why?
|
| Antigens, Viral | 1 | 2004 | 992 | 0.170 |
Why?
|
| Female | 40 | 2024 | 396943 | 0.170 |
Why?
|
| Vaccines, Synthetic | 2 | 1999 | 622 | 0.160 |
Why?
|
| Aged | 21 | 2024 | 171520 | 0.160 |
Why?
|
| Crohn Disease | 1 | 2012 | 2293 | 0.160 |
Why?
|
| Legislation, Medical | 1 | 2019 | 98 | 0.160 |
Why?
|
| Antigens | 1 | 2004 | 1443 | 0.160 |
Why?
|
| Antiviral Agents | 2 | 2021 | 3063 | 0.150 |
Why?
|
| Antibody Formation | 3 | 2013 | 1393 | 0.150 |
Why?
|
| Immunoglobulin G | 6 | 2011 | 4572 | 0.150 |
Why?
|
| Young Adult | 12 | 2020 | 60045 | 0.150 |
Why?
|
| Obesity | 1 | 2020 | 13065 | 0.140 |
Why?
|
| beta-Lactamases | 1 | 2019 | 307 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 1544 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 7 | 2023 | 7471 | 0.140 |
Why?
|
| Bacteria | 3 | 2017 | 2226 | 0.140 |
Why?
|
| Ampicillin | 2 | 2014 | 137 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 59680 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 4213 | 0.130 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2014 | 166 | 0.130 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 590 | 0.130 |
Why?
|
| Transferases | 1 | 1996 | 71 | 0.130 |
Why?
|
| Vaccines | 1 | 2004 | 845 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2016 | 2444 | 0.130 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1996 | 87 | 0.130 |
Why?
|
| Freezing | 1 | 2016 | 311 | 0.130 |
Why?
|
| Gastroenteritis | 2 | 2012 | 236 | 0.130 |
Why?
|
| Intestine, Small | 2 | 2013 | 1218 | 0.120 |
Why?
|
| RNA, Bacterial | 3 | 2011 | 393 | 0.120 |
Why?
|
| Nitric Oxide | 2 | 2022 | 2146 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2019 | 1840 | 0.120 |
Why?
|
| Safety | 1 | 2019 | 1159 | 0.120 |
Why?
|
| Double-Blind Method | 4 | 2022 | 12450 | 0.120 |
Why?
|
| Salmonella | 3 | 2001 | 125 | 0.110 |
Why?
|
| Child | 12 | 2018 | 80863 | 0.110 |
Why?
|
| Membrane Proteins | 3 | 2006 | 7895 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2010 | 8051 | 0.110 |
Why?
|
| Spasm | 1 | 2014 | 131 | 0.110 |
Why?
|
| Lipopolysaccharides | 5 | 2013 | 2216 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 3816 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 1176 | 0.110 |
Why?
|
| Transdermal Patch | 1 | 2013 | 52 | 0.110 |
Why?
|
| Uridine Diphosphate | 1 | 2013 | 34 | 0.110 |
Why?
|
| HIV-1 | 2 | 2011 | 6966 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3116 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3240 | 0.100 |
Why?
|
| Intestinal Mucosa | 4 | 2013 | 3048 | 0.100 |
Why?
|
| Virulence | 5 | 2009 | 1303 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2018 | 5709 | 0.100 |
Why?
|
| Gentamicins | 1 | 2013 | 245 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2020 | 2181 | 0.100 |
Why?
|
| Drug Approval | 1 | 2019 | 817 | 0.100 |
Why?
|
| Operon | 1 | 1993 | 372 | 0.100 |
Why?
|
| Ecosystem | 1 | 2016 | 494 | 0.100 |
Why?
|
| Gene Expression Regulation, Bacterial | 4 | 2009 | 1139 | 0.100 |
Why?
|
| Peritoneal Lavage | 1 | 2011 | 31 | 0.090 |
Why?
|
| Nucleocapsid Proteins | 1 | 2011 | 78 | 0.090 |
Why?
|
| Hemolysin Proteins | 1 | 2011 | 113 | 0.090 |
Why?
|
| Research Subjects | 1 | 2013 | 249 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 716 | 0.090 |
Why?
|
| Immunoglobulin A | 3 | 2000 | 990 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 13026 | 0.090 |
Why?
|
| Paratyphoid Fever | 1 | 2010 | 34 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 1669 | 0.090 |
Why?
|
| Time Factors | 6 | 2020 | 40271 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 3 | 2007 | 6241 | 0.090 |
Why?
|
| Ethical Review | 2 | 2013 | 27 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 1339 | 0.090 |
Why?
|
| Rural Population | 2 | 2018 | 2317 | 0.090 |
Why?
|
| Mice | 17 | 2014 | 82045 | 0.080 |
Why?
|
| DNA, Bacterial | 2 | 2010 | 1474 | 0.080 |
Why?
|
| Military Personnel | 1 | 2019 | 1264 | 0.080 |
Why?
|
| Flagellin | 1 | 2010 | 124 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2019 | 1400 | 0.080 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2010 | 120 | 0.080 |
Why?
|
| Cryopreservation | 1 | 2014 | 731 | 0.080 |
Why?
|
| Colonoscopy | 2 | 2014 | 1412 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2010 | 706 | 0.080 |
Why?
|
| Peritonitis | 1 | 2011 | 368 | 0.080 |
Why?
|
| Vaccination | 3 | 2011 | 3434 | 0.080 |
Why?
|
| HIV Infections | 3 | 2011 | 17564 | 0.080 |
Why?
|
| Blood | 1 | 2010 | 597 | 0.070 |
Why?
|
| Gene Deletion | 1 | 1996 | 2674 | 0.070 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2010 | 208 | 0.070 |
Why?
|
| Sulfur Isotopes | 1 | 2007 | 21 | 0.070 |
Why?
|
| Canada | 2 | 2023 | 2143 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 798 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2013 | 1561 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2014 | 1126 | 0.070 |
Why?
|
| Boston | 1 | 2020 | 9361 | 0.070 |
Why?
|
| Actinomyces | 1 | 2006 | 41 | 0.070 |
Why?
|
| Metagenome | 1 | 2010 | 465 | 0.070 |
Why?
|
| Macrophages | 2 | 2007 | 5797 | 0.070 |
Why?
|
| Vaccines, Inactivated | 1 | 2007 | 185 | 0.070 |
Why?
|
| Animals | 18 | 2014 | 169418 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2022 | 81834 | 0.070 |
Why?
|
| HIV Core Protein p24 | 1 | 2006 | 247 | 0.070 |
Why?
|
| Oxygen | 3 | 2022 | 4269 | 0.070 |
Why?
|
| U937 Cells | 1 | 2006 | 260 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 359 | 0.060 |
Why?
|
| Bacterial Toxins | 1 | 2011 | 926 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2016 | 5308 | 0.060 |
Why?
|
| Nepal | 2 | 2018 | 301 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 882 | 0.060 |
Why?
|
| Government Regulation | 1 | 2009 | 525 | 0.060 |
Why?
|
| Spleen | 2 | 2010 | 2298 | 0.060 |
Why?
|
| Physicians | 1 | 2022 | 4615 | 0.060 |
Why?
|
| Species Specificity | 3 | 2016 | 2422 | 0.060 |
Why?
|
| Cognition | 1 | 2022 | 7066 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2010 | 630 | 0.060 |
Why?
|
| Dependovirus | 1 | 2009 | 720 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 1892 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 18388 | 0.060 |
Why?
|
| Debridement | 1 | 2006 | 494 | 0.060 |
Why?
|
| Mice, Knockout | 7 | 2014 | 14480 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 3735 | 0.050 |
Why?
|
| Monkeypox virus | 1 | 2023 | 43 | 0.050 |
Why?
|
| Plasmids | 2 | 2000 | 2269 | 0.050 |
Why?
|
| Colitis | 1 | 2011 | 1244 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2004 | 485 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 8 | 2014 | 22365 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 1100 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2006 | 709 | 0.050 |
Why?
|
| Focal Infection | 1 | 2001 | 9 | 0.050 |
Why?
|
| United States | 4 | 2021 | 73121 | 0.050 |
Why?
|
| Azetidines | 1 | 2022 | 143 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 13497 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2011 | 1177 | 0.050 |
Why?
|
| Transcription Factors | 4 | 1998 | 12174 | 0.050 |
Why?
|
| Food Microbiology | 1 | 2001 | 74 | 0.050 |
Why?
|
| Singapore | 1 | 2021 | 298 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 2411 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2018 | 42623 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 3438 | 0.040 |
Why?
|
| Research Personnel | 1 | 2005 | 591 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2001 | 200 | 0.040 |
Why?
|
| Attitude | 1 | 2005 | 773 | 0.040 |
Why?
|
| Students, Medical | 1 | 2013 | 1962 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 587 | 0.040 |
Why?
|
| Drugs, Investigational | 1 | 2021 | 213 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 766 | 0.040 |
Why?
|
| Bangladesh | 2 | 2011 | 735 | 0.040 |
Why?
|
| Fluoroquinolones | 1 | 2001 | 309 | 0.040 |
Why?
|
| Salmonella Infections, Animal | 1 | 1998 | 60 | 0.040 |
Why?
|
| Massachusetts | 2 | 2023 | 8908 | 0.040 |
Why?
|
| Purines | 1 | 2022 | 614 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2005 | 997 | 0.040 |
Why?
|
| Cause of Death | 1 | 2009 | 3727 | 0.040 |
Why?
|
| Interleukin-8 | 2 | 2013 | 705 | 0.040 |
Why?
|
| Disease Notification | 1 | 2018 | 95 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2002 | 1230 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20231 | 0.040 |
Why?
|
| Genetic Research | 1 | 2019 | 173 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 9507 | 0.040 |
Why?
|
| Meningoencephalitis | 1 | 1998 | 83 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 830 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2020 | 1170 | 0.040 |
Why?
|
| Risk Factors | 3 | 2023 | 74915 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2013 | 3463 | 0.040 |
Why?
|
| Japan | 1 | 2021 | 1418 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 417 | 0.030 |
Why?
|
| Patient Selection | 1 | 2009 | 4266 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2000 | 660 | 0.030 |
Why?
|
| Syndrome | 1 | 2023 | 3278 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 54914 | 0.030 |
Why?
|
| 3-Phosphoshikimate 1-Carboxyvinyltransferase | 1 | 1996 | 6 | 0.030 |
Why?
|
| Infant | 3 | 2014 | 36497 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 13452 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 14728 | 0.030 |
Why?
|
| Proteomics | 1 | 2009 | 3901 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 17647 | 0.030 |
Why?
|
| Biodiversity | 1 | 2018 | 346 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2011 | 4567 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1998 | 808 | 0.030 |
Why?
|
| Morganella morganii | 1 | 2014 | 5 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2022 | 1965 | 0.030 |
Why?
|
| Streptomycin | 1 | 2014 | 69 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 851 | 0.030 |
Why?
|
| Pregnancy | 4 | 2022 | 30179 | 0.030 |
Why?
|
| Deoxyribonucleotides | 1 | 2014 | 43 | 0.030 |
Why?
|
| Mutation | 4 | 2009 | 30243 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 3763 | 0.030 |
Why?
|
| Starvation | 1 | 2014 | 141 | 0.030 |
Why?
|
| Registries | 1 | 2010 | 8373 | 0.030 |
Why?
|
| Mouth | 1 | 2016 | 383 | 0.030 |
Why?
|
| Acute Disease | 1 | 2024 | 7246 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 987 | 0.030 |
Why?
|
| Absorption | 1 | 2013 | 243 | 0.030 |
Why?
|
| Temperature | 1 | 2000 | 2237 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 1764 | 0.030 |
Why?
|
| Azo Compounds | 1 | 2013 | 116 | 0.030 |
Why?
|
| Microvilli | 1 | 2013 | 235 | 0.030 |
Why?
|
| Enterococcus faecalis | 1 | 2014 | 245 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2013 | 5952 | 0.030 |
Why?
|
| Phenylalanine | 1 | 2014 | 366 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 476 | 0.030 |
Why?
|
| Informed Consent | 1 | 2019 | 1012 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2022 | 1988 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1996 | 1497 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 1993 | 373 | 0.020 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2013 | 151 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2022 | 2024 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2016 | 1972 | 0.020 |
Why?
|
| Gram-Negative Aerobic Bacteria | 1 | 2010 | 8 | 0.020 |
Why?
|
| Gram-Negative Anaerobic Bacteria | 1 | 2010 | 15 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 1379 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2013 | 962 | 0.020 |
Why?
|
| Bacterial Translocation | 1 | 2010 | 74 | 0.020 |
Why?
|
| Pandemics | 2 | 2020 | 8753 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2011 | 131 | 0.020 |
Why?
|
| Communication | 1 | 2005 | 3910 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2011 | 163 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2010 | 192 | 0.020 |
Why?
|
| Environment | 1 | 2016 | 1126 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2011 | 258 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6537 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 41797 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2010 | 767 | 0.020 |
Why?
|
| Language | 1 | 2019 | 1557 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1482 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2723 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2013 | 918 | 0.020 |
Why?
|
| DNA Primers | 1 | 2013 | 2826 | 0.020 |
Why?
|
| Models, Biological | 2 | 2018 | 9505 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 752 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 2003 | 0.020 |
Why?
|
| Peroxidase | 1 | 2011 | 610 | 0.020 |
Why?
|
| Cell Line | 2 | 2013 | 15609 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1995 | 5042 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2010 | 1992 | 0.020 |
Why?
|
| Computer-Assisted Instruction | 1 | 2010 | 364 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 582 | 0.020 |
Why?
|
| Prevalence | 1 | 2023 | 15880 | 0.020 |
Why?
|
| Abscess | 1 | 2010 | 607 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2010 | 1051 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2011 | 12813 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2010 | 1438 | 0.020 |
Why?
|
| Steroids | 1 | 2011 | 937 | 0.020 |
Why?
|
| Liver | 2 | 2013 | 7575 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10125 | 0.020 |
Why?
|
| Triglycerides | 1 | 2013 | 2465 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2022 | 4877 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 10273 | 0.010 |
Why?
|
| Cattle | 1 | 2010 | 3830 | 0.010 |
Why?
|
| Abdomen | 1 | 2010 | 1136 | 0.010 |
Why?
|
| Phosphorylation | 2 | 2010 | 8332 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4586 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 3794 | 0.010 |
Why?
|
| Phylogeny | 1 | 2010 | 2846 | 0.010 |
Why?
|
| Immunoassay | 1 | 2006 | 746 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 7599 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2016 | 6278 | 0.010 |
Why?
|
| Skin | 1 | 2016 | 4520 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2010 | 1397 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 1993 | 2987 | 0.010 |
Why?
|
| Developing Countries | 1 | 2013 | 2901 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2010 | 3234 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2010 | 2485 | 0.010 |
Why?
|
| Homeostasis | 1 | 2010 | 3351 | 0.010 |
Why?
|
| Meningitis, Listeria | 1 | 1998 | 4 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2010 | 3472 | 0.010 |
Why?
|
| Critical Care | 1 | 2011 | 2717 | 0.010 |
Why?
|
| Brain Abscess | 1 | 1998 | 123 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1998 | 916 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 4368 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2013 | 19041 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 10601 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2011 | 9382 | 0.010 |
Why?
|
| Cytokines | 1 | 2011 | 7449 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 26351 | 0.010 |
Why?
|
| Th1 Cells | 1 | 1998 | 1044 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1998 | 977 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2002 | 2959 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2011 | 15880 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2002 | 26395 | 0.000 |
Why?
|
| Inflammation | 1 | 1998 | 10865 | 0.000 |
Why?
|